We are committed to finding a safe, effective, and patient-friendly therapy for food and pediatric allergy patients




LEERINK Partners Annual Emerging Biotech Conference

Snowbird, Utah

Scientific publications

Sustainability of Phenotype and Suppressive Activities of Tregs after Discontinuation of EPIT® but Not of OIT or SLIT Peanut Sensitized Mice

No Impact of Filaggrin Deficiency on EPIT® in a Murine Model

Epicutaneous Immunotherapy Using PlasmaDerived Factor VIII Reduces the Inhibitor Immune Response to Therapeutic Factor VIII in Experimental Hemophilia a

Corporate video